Resources for Patients and their Families
Request Free Guide

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Brief Summary

The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG PET scans.

Tracking Information
First Received DateSeptember 15, 2010
Last Changed DateApril 24, 2017
Start DateJune 2009
Actual Primary Completion DateApril 2015
Primary Outcome Measures

Tumor Response Rate Following Zoledronic Acid (Zometa) [Time Frame: Baseline up to 28 months or until progressive disease or death]

Secondary Outcome Measures

Progression Free Survival (PFS) [Time Frame: Baseline up to 28 months]

Overall Survival (OS) [Time Frame: Baseline up to 28 months]

Descriptive Information
PhasePhase 2
Study TypeInterventional
  • Mesothelioma
  • Drug: Zometa
Study Arms / Comparison Groups1 / 0
Detailed Description

This pilot study will examine the effect of bisphosphonate (zoledronic acid) in patients with malignant mesothelioma. Evaluation will be limited to patients with standard (CT scans) and functional instruments (FDG PET Scans) of tumor assessment after the administration of standard doses of zoledronic acid (4 mg IV every 3 weeks). We will also explore the biologic effect of zoledronic acid in patients using new serum markers as well as several blood level markers.

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment8
Ages19 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Males and females > 18 years of age

- Life expectancy of at least 2 months

- Histologically confirmed unresectable malignant pleural mesothelioma (MPM)

- Measurable disease by CT Scan criteria and/or positive metabolic activity of 18F-FDG PET Scan criteria at screening

- ECOG Performance Status of 0-2

- Laboratory and clinical results within 2 weeks prior to Day 1 must be as follows:

1. ANC ≥ 1.5 x 109/L

2. Platelet Count ≥ 100 x 109/L

3. Hemoglobin ≥ 9g/dL

4. Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)

5. AST ≤ 2.5 x ULN

6. ALT ≤ 2.5 x ULN

7. ALK-P ≤ 3 x ULN

8. Serum creatinine ≤ 1.8mg/dL

9. Calculated Serum Creatinine Clearance 40 - > 60ml/min

- Female subjects of childbearing potential and all male subjects must be surgically sterile or consent to use a medically acceptable method of contraception throughout the trial.

- Willing and able to provide written informed consent.

Exclusion Criteria:

- Known central nervous system (CNS) tumor involvement

- Evidence of other active malignancy requiring treatment

- Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class 3 or 4 angina not well controlled by medication, or myocardial infarction within 6 months)

- Known infection with HIV or hepatitis

- Clinically significant arrhythmias demonstrated on electrocardiogram (ECG). Note: subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia (SVT) are eligible.

- Active, serious systemic disease, including active bacterial or fungal infection.

- Subjects undergoing invasive dental procedures, significant periodontal disease or history of osteonecrosis of the jaw.

- Treatment within 4 weeks of the start of the trial with other systemic anticancer therapy.

- Breastfeeding, pregnant, or likely to become pregnant during the clinical trial.

Administrative Information
Responsible PartyPrincipal Investigator
SponsorUniversity of Alabama at Birmingham
Verification DateApril 2017
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: